1[1]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2):485 被引量：1
2[2]Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreatedwith anthracyclines. Br J Cancer, 2002, 86 (9):1367 被引量：1
3[3]Meta-analysis goup in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced coleorectal cancer. J Clin Oneol. 1998, 16:301 被引量：1
4[4]Meta-analysis group in carcer. Toxicity of fiuorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol, 1998, 16:3537 被引量：1
5[5]Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Inter Med, 1984, 101 :798 被引量：1
6[6]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2) :485 被引量：1
7[7]Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palar-plantar erythrodysesthesia syndrome. Ann Inter Med,1989, 111:688 被引量：1
8[8]Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs, 1990, 8:57 被引量：1
9[9]Jucgla A, Sais G. Hand-foot syndrome. J Clin Oncol, 1997, 15: 3164 被引量：1
10[10]Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: Efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol, 1990, 26:449 被引量：1
